Literature DB >> 9315696

The role of creatine kinase in inhibition of mitochondrial permeability transition.

E O'Gorman1, G Beutner, M Dolder, A P Koretsky, D Brdiczka, T Wallimann.   

Abstract

Cyclosporin A sensitive swelling of mitochondria isolated from control mouse livers and from the livers of transgenic mice expressing human ubiquitous mitochondrial creatine kinase occurred in the presence of both 40 microM calcium and 5 microM atractyloside which was accompanied by a 2.5-fold increase over state 4 respiration rates. Creatine and cyclocreatine inhibited the latter only in transgenic liver mitochondria. Protein complexes isolated from detergent solubilised rat brain extracts, containing octameric mitochondrial creatine kinase, porin and the adenine nucleotide translocator, were reconstituted into malate loaded lipid vesicles. Dimerisation of creatine kinase in the complexes and exposure of the reconstituted complexes to >200 microM calcium induced a cyclosporin A sensitive malate release. No malate release occurred with complexes containing octameric creatine kinase under the same conditions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9315696     DOI: 10.1016/s0014-5793(97)01045-4

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  47 in total

Review 1.  Antioxidants in Huntington's disease.

Authors:  Ashu Johri; M Flint Beal
Journal:  Biochim Biophys Acta       Date:  2011-11-23

2.  Tyrosine impairs enzymes of energy metabolism in cerebral cortex of rats.

Authors:  Rodrigo Binkowski de Andrade; Tanise Gemelli; Denise Bertin Rojas; Cláudia Funchal; Carlos Severo Dutra-Filho; Clovis Milton Duval Wannmacher
Journal:  Mol Cell Biochem       Date:  2012-02-05       Impact factor: 3.396

3.  Inhibition of cytosolic and mitochondrial creatine kinase by siRNA in HaCaT- and HeLaS3-cells affects cell viability and mitochondrial morphology.

Authors:  Holger Lenz; Melanie Schmidt; Vivienne Welge; Thomas Kueper; Uwe Schlattner; Theo Wallimann; Hans-Peter Elsässer; Klaus-Peter Wittern; Horst Wenck; Franz Staeb; Thomas Blatt
Journal:  Mol Cell Biochem       Date:  2007-07-28       Impact factor: 3.396

Review 4.  The mitochondrial permeability transition in neurologic disease.

Authors:  M D Norenberg; K V Rama Rao
Journal:  Neurochem Int       Date:  2007-03-04       Impact factor: 3.921

Review 5.  Regulation and pharmacology of the mitochondrial permeability transition pore.

Authors:  Dmitry B Zorov; Magdalena Juhaszova; Yael Yaniv; H Bradley Nuss; Su Wang; Steven J Sollott
Journal:  Cardiovasc Res       Date:  2009-05-15       Impact factor: 10.787

Review 6.  Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases.

Authors:  Peter J Adhihetty; M Flint Beal
Journal:  Neuromolecular Med       Date:  2008-11-13       Impact factor: 3.843

7.  Mitochondrial therapies for Parkinson's disease.

Authors:  Bobby Thomas; M Flint Beal
Journal:  Mov Disord       Date:  2010       Impact factor: 10.338

Review 8.  Current perspective of mitochondrial biology in Parkinson's disease.

Authors:  Navneet Ammal Kaidery; Bobby Thomas
Journal:  Neurochem Int       Date:  2018-03-14       Impact factor: 3.921

9.  VDAC and peripheral channelling complexes in health and disease.

Authors:  Mikhail Vyssokikh; Dieter Brdiczka
Journal:  Mol Cell Biochem       Date:  2004 Jan-Feb       Impact factor: 3.396

10.  ASB9 interacts with ubiquitous mitochondrial creatine kinase and inhibits mitochondrial function.

Authors:  Sanghoon Kwon; Dongbum Kim; Jae Won Rhee; Jeong-A Park; Dae-Won Kim; Doo-Sik Kim; Younghee Lee; Hyung-Joo Kwon
Journal:  BMC Biol       Date:  2010-03-19       Impact factor: 7.431

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.